ROS1 and non-small cell lung carcinoma: The SA-PRO population (N = 268) comprised 88 patients with locally advanced/metastatic NTRK fusion-positive solid tumours and 180 patients with locally advanced/metastatic ROS1 fusion-positive NSCLC.